View Post

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com The PARP inhibitor veliparib increased progression-free survival (PFS) in women with hormone receptor (HR)-positive breast cancer and triple-negative breast cancer (TNBC) who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694), presented during the 2020 ESMO Breast Cancer Virtual Meeting. “In both subgroups, …

View Post

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: biospace.com AWARE-1 trial demonstrates pelareorep primes an adaptive immune response Systemic delivery yields robust pelareorep replication selectively in tumor cells Pelareorep administration increases CelTIL – known to be associated with positive clinical outcomes Peripheral T cell clonality emerges as potential predictive and prognostic biomarker Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, …

View Post

Ipatasertib Survival Results Continue to Impress in TNBC

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderic From: onclive.com Adding the oral AKT inhibitor ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival (OS) in patients with locally advanced or metastatic triple-negative breast cancer (TNBC), according to the final analysis of the phase 2 LOTUS trial presented during the 2020 ESMO breast cancer virtual meeting.1 In the intention-to-treat (ITT) …

View Post

Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel

In Clinical Studies News by Barbara Jacoby

From: .pcf.org Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA Major clinical trial heralds approval as first gene-targeted drug in prostate cancer A drug already licensed for the treatment of breast and ovarian cancers is more effective than …

View Post

FDA Approves Novartis’ Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com The US Food and Drug Administration on Wednesday approved capmatinib (Novartis’ Tabrecta) for treatment of patients with metastatic non-small cell lung cancer. The agency also approved Foundation Medicine’s FoundationOne CDx assay, a broad comprehensive genomic profiling test for solid tumors, as a companion diagnostic for the drug. A companion diagnostic for capmatinib with Foundation’s liquid …

View Post

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

In Clinical Studies News by Barbara Jacoby

By: Ellie Leick From: onclive.com The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA-mutated breast cancer in recent years, according to Melinda L. Telli, MD, and research efforts are now examining these agents in novel combinations and beyond the BRCA setting. In January 2018, olaparib (Lynparza) joined the treatment arsenal for use as a …

View Post

Fractures and the Use of Bisphosphonates in Patients With Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: oncnet.com In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discussed findings from the SWOG S0307 trial, which looked at the occurrence of fractures in patients with breast cancer receiving high-dose bisphosphonates to prevent metastases. Transcript I’m Dr Julie Gralow. I’m a Professor of Breast Medical Oncology …

View Post

Researchers Report Positive Preliminary Data, Favorable Safety Update for Pelareorep in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Aislinn Antrim, Assistant Editor From: pharmacytimes.com The Safety Committee evaluating Onclytics Biotech Inc’s pelareorep has found no safety concerns after evaluating the first 3 cohorts.1 Early findings from the AWARE-1 trial investigating pelareorep for early-stage breast cancer have found that T cell clonality may support the development of a biomarker for the disease, according to a press release.2 More …

View Post

BRCA1/2-Positive Breast Cancer Patients May Respond to Certain Chemotherapy Regimens, Study Finds

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Researchers have homed in on BRCA1/2 mutations as a potential biomarker predictive of which early-stage breast cancer patients will respond to a neoadjuvant chemotherapy regimen containing epirubicin, paclitaxel, cyclophosphamide (iddEPC). Esther Pohl-Rescigno from University Hospital Cologne in Germany led the study published in JAMA Oncology last week. The secondary analysis was based on the 961-patient …

View Post

Addition of ICIs to Neoadjuvant Chemotherapy in High-Risk Breast Cancer Supported by Results of Phase 3 Trial

In Clinical Studies News by Barbara Jacoby

By: Susan Moench, PhD, PA-C From: cancertherapyadvisor.com The pathologic complete response (pCR) rate was nearly 14% higher for women with high-risk nonmetastatic triple-negative breast cancer (TNBC) treated with a neoadjuvant treatment regimen including chemotherapy plus an immune checkpoint inhibitor (ICI) compared with chemotherapy alone, according to results of a phase 3 study published in the New England Journal of Medicine.1 …